Mepolizumab (Nucala)

Mepolizumab (Nucala) is covered as add‑on maintenance therapy for severe eosinophilic asthma (age ≥6) and for eosinophilic granulomatosis with polyangiitis (EGPA) in adults (age ≥18); no off‑label compendial uses are approved. Coverage requires a blood eosinophil count ≥150 cells/µL within 6 weeks, specialist prescribing/consultation, for asthma a prior ≥3‑month trial of an inhaled corticosteroid plus at least one additional controller (unless already on anti‑IL‑5), documented uncontrolled asthma, and demonstration of clinical benefit after ≥6 months for reauthorization (EGPA also requires ≥4 weeks of corticosteroid therapy prior to approval).

"Add-on maintenance treatment of individuals with severe asthma having an eosinophilic phenotype."

Sign up to see full coverage criteria, indications, and limitations.